PF 3084014

Drug Profile

PF 3084014

Alternative Names: PF-03084014; PF-3084014

Latest Information Update: 11 Apr 2017

Price : $50

At a glance

  • Originator Pfizer
  • Developer Jules Bordet Institute; National Cancer Institute (USA); Pfizer
  • Class Amides; Antineoplastics; Imidazoles; Naphthalenes; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fibroma; Pancreatic cancer
  • Phase I Acute lymphoblastic leukaemia; Lymphoid leukaemia; Solid tumours; T-cell leukaemia
  • Discontinued Alzheimer's disease; Breast cancer

Most Recent Events

  • 08 Feb 2017 Pfizer initiates a compassionate use protocol of PF 03084014 in Solid tumour in USA (NCT02955446)
  • 02 Nov 2016 Pfizer plans a compassionate use protocol of PF 03084014 in Solid tumour in USA (NCT02955446)
  • 01 Nov 2016 Pfizer completes a phase I trial in Solid tumours, T-cell leukaemia, acute lymphoblastic leukaemia and lymphoid leukaemia (Late-stage disease, Second-line therapy or greater, In adolescents, In adults, In the elderly) in USA and Italy (NCT00878189)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top